Overview of Levomepromazin

Property	Description
Active ingredient	Levomepromazine (Methotrimeprazine)
Primary Forms	Tablets, Oral Solution, Solution for Injection
Pharmacological Class	Typical Antipsychotic (First-Generation Neuroleptic)
Origin	Synthetic Compound (Phenothiazine derivative)
Core Function	Central Nervous System Stabilization and Sedation

What Type of Medicine is Levomepromazine?

Levomepromazine is a synthetic pharmaceutical compound officially classified as a Typical Antipsychotic, also widely referred to as a First-Generation Neuroleptic. The active substance is a prescription-only medicine that originates from the phenothiazine chemical structure. This classification places it within a group of established medicines that are clinically recognized for their ability to stabilize severe disturbances of thought and mood. Levomepromazine is specifically known as a low-potency agent within the typical class, a characteristic that results in its substantial sedative and calming properties in addition to its primary stabilizing function.

Forms, Composition, and Core Function

This medicine is a single-ingredient product available for both oral and parenteral routes of administration, supplied as oral tablets, an oral solution, and a solution for injection in ampoules. The active component is the Levomepromazine salt, which is formulated with the necessary pharmaceutical excipients for each final presentation. The comprehensive action of the drug on the central nervous system establishes its core function as a potent depressant and stabilizing agent, making it critical for the rapid reduction of intense agitation and severe mental distress. The availability of multiple forms allows for flexibility in patient care, ranging from routine oral use to acute interventions.

Levomepromazine: A Compound with Broad Sedative Action

Levomepromazine's utility is defined by its broad-spectrum receptor antagonism, which results in its powerful sedative and calming effects. While it stabilizes severe thought disturbances through its primary action, its strong non-selective blockade of various receptors (including histamine) delivers the profound calming profile. This mechanism results in the compound's effectiveness for inducing tranquilization and rest. Consequently, Levomepromazine is frequently utilized as an effective analgesic adjunct, supporting the management of severe pain by modulating central pain perception and promoting overall patient relaxation.

What side effects are possible with Levomepromazin?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety characteristics of Levomepromazine, strictly based on government regulatory prescribing information (e.g., FDA, EMA, and national health agencies).

Documented Adverse Reactions

The most Common adverse reactions listed in regulatory documents reflect the drug's potent sedative and vascular effects, and typically include drowsiness (somnolence) and postural hypotension (dizziness or lightheadedness when standing up). Less frequent effects include dry mouth, constipation, and urinary retention.

Classification	Examples of Documented Effects
Common	Drowsiness, Postural Hypotension, Asthenia
Uncommon	Urinary retention, Photosensitivity
Rare	Neuroleptic Malignant Syndrome (NMS), Cholestatic Jaundice
Very Rare	Agranulocytosis, Torsades de pointes

Serious Safety Considerations

The label documents several rare but clinically significant adverse reactions. These include potentially fatal conditions such as Neuroleptic Malignant Syndrome (NMS), a severe neurological disorder, and serious cardiac risks including QT interval prolongation which may lead to Torsades de pointes (a severe ventricular arrhythmia) and sudden death. Other serious risks include Agranulocytosis (a severe blood disorder) and an increased risk of Venous Thromboembolism (VTE).

Population and Time-Related Safety

Elderly patients are officially noted to be more susceptible to postural hypotension and extrapyramidal effects. For patients with dementia-related psychosis, there is a documented increased risk of stroke/cerebrovascular events. Some effects, such as hypotension, are more frequent at the initiation of treatment, while Tardive Dyskinesia is associated with long-term exposure.

Safety constraints necessitate avoidance in patients with a history of agranulocytosis or conditions like closed-angle glaucoma or urinary retention risk. Caution is required in patients with cardiac disease or epilepsy.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory authorities require that individuals seek immediate medical attention upon suspected Levomepromazine overdose. Contacting a doctor or the nearest hospital casualty department is mandated due to the risk of severe, life-threatening outcomes. The official guidance classifies this scenario as potentially severe due to the documented risk of cardiac events.

Overdose presentations affect multiple physiological systems as described in regulatory labeling:

System Affected	Documented Manifestations
Central Nervous System	Drowsiness, Loss of consciousness, Convulsions, Severe extrapyramidal dyskinesias
Cardiovascular	Hypotension, Tachycardia, Irregular heartbeats, ECG changes

The most serious manifestations involve the cardiovascular system, including potentially life-threatening ventricular arrhythmias and Torsades de pointes, which can lead to circulatory collapse or sudden death.

Immediate Response and Supportive Care

Treatment is strictly symptomatic and supportive because official regulatory documents state that no specific antidote is known. Management may include continuous monitoring of cardiac rhythm and vital signs, along with procedures such as the administration of activated charcoal. Elderly patients are noted to be more susceptible to the manifestation of hypotension in this context.

Therapeutic Uses of Levomepromazin

What Levomepromazine Treats: Main Uses and Benefits

Levomepromazine is commonly used in therapeutic domains where supportive symptomatic support is needed, especially in situations where patients experience highly distressing symptoms and temporary instability. Its use is generally relevant in contexts where supportive symptom management is appropriate.

This medication is generally used to help address symptom clusters associated with conditions characterized by periods of heightened symptoms, such as schizophrenia and bipolar disorder. Its use is relevant for managing pronounced manifestations like hallucinations, delusions, immediate behavioral disturbances like agitation and excitement, as well as severe pain, sleep deficits, and nausea/vomiting.

The key therapeutic benefit is support for stabilization, and may assist with easing the overall symptom load during difficult episodes. The medication may be part of symptomatic management to help manage the patient's overall symptom burden, particularly in supportive care.

“It is commonly applied in scenarios where supportive symptomatic assistance is needed, especially during phases of increased distress.”

Quick Fact: Support for Acute Symptom Management

Levomepromazine supports patients during acute episodes by managing symptoms related to heightened physiological activity and severe emotional tension, assists with maintaining functional stability when symptoms become more noticeable.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Rules

Regulatory documentation defines strict eligibility criteria for Levomepromazine, primarily establishing the medicine for use in adults who do not present with specific contraindicated conditions. Use is generally not recommended for the pediatric and adolescent populations.

Category	Official Regulatory Statement
Populations for whom use is contraindicated	Patients with known hypersensitivity to Levomepromazine or any other phenothiazine derivative. Individuals with a history of agranulocytosis, porphyria, or angle-closure glaucoma. Contraindicated for those taking medicines that cause QTc prolongation or in cases of acute alcohol or CNS depressant intoxication.
Age-Related Eligibility	Established use is for Adults. Use is not recommended in children and adolescents. Older adults require caution due to increased susceptibility to effects like orthostatic hypotension and sedation.
Conditional Use Restrictions	Use requires caution in patients with hepatic impairment (liver dysfunction) or renal impairment (kidney dysfunction). Caution is also advised in severe cardiovascular disease, epilepsy, or in patients with a history of urinary retention.
Pregnancy and Lactation Status	Not recommended during pregnancy (especially the third trimester due to neonatal risk) or while breastfeeding. A decision to discontinue one or the other must be made.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Levomepromazine's interaction profile involves both pharmacodynamic and pharmacokinetic mechanisms, affecting the exposure of other medicines and increasing the risk of certain side effects.

Clinically Significant Interactions

Category	Practical Constraint & Mechanism
CNS Depressants & Alcohol	Additive depressant effects. Avoid alcohol/medicines containing alcohol. Use with caution/modified doses of narcotic analgesics.
Medicines that Prolong QT Interval	Increased risk of severe ventricular rhythm disorders (Torsades de pointes). This combination is generally avoided.
CYP2D6 Substrates	Levomepromazine is a potent inhibitor of CYP2D6, which may increase the plasma concentrations of co-administered medicines metabolized by this enzyme.
Antihypertensives	Additive hypotensive effects; this must be considered, particularly in the elderly.
Drugs Causing Electrolyte Imbalance	Avoid diuretics that cause hypokalaemia, as this increases the risk of heart rhythm disturbances. Potassium-sparing diuretics are preferred.

Official Regulatory Requirements

Due to the significant risk of cardiac arrhythmias, co-administration is restricted with other agents known to prolong the QT interval or cause electrolyte imbalance, which can predispose the heart to Torsades de pointes. The consumption of alcoholic beverages must be avoided during treatment. When combined with other CNS depressants, the dose may require adjustment to mitigate excessive sedation. The pharmacokinetic impact as a CYP2D6 inhibitor necessitates caution and appropriate monitoring when initiating treatment with co-administered CYP2D6 substrate drugs.

Mechanism of Action

How Levomepromazine Works

Targeting Neurotransmitter Signaling Pathways

Levomepromazine acts as an antagonist at several receptor types in the central nervous system (CNS), blocking the action of multiple chemical messengers. Key targets include dopamine receptors (e.g., D2) and serotonin receptors (5-HT2), which are involved in regulating neural communication. The receptor antagonism alters nerve cell communication, resulting in reduced signaling intensity in these pathways.

Mechanism of Action on Arousal and Autonomic Systems

The resulting physiological effect on central nervous system activity is linked to receptor antagonism at H1 histamine and alpha-1 adrenergic receptors. H1 receptor antagonism in the CNS mediates a marked depression of arousal pathways. Alpha-1 adrenergic receptor antagonism affects the autonomic nervous system, which results in altered vascular tone. Antagonism of muscarinic acetylcholine receptors produces peripheral anticholinergic consequences.

Dosage and Administration Information

Administration Scope

Feature	Instruction
Route of Administration	The drug is for oral use (tablets, solution), as well as intramuscular (IM) injection, intravenous (IV) injection, and continuous subcutaneous (SC) infusion.
Dosing Schedule	Initial daily oral doses for ambulatory patients should generally not exceed 25 mg to 50 mg; bedridden patients may start at 100 mg to 200 mg. Parenteral doses for acute use range from 12.5 mg to 25 mg per administration.
Timing in relation to meals	Instructions generally do not specify administration relative to food.
Preparation Requirements	IV injection requires immediate dilution with an equal volume of normal saline (Sodium Chloride 0.9%) prior to use. Continuous SC infusion also requires dilution, typically with normal saline.
Age-Group Administration Rules	A lower initial dosage is recommended for older adults, and the total daily oral dose for children should not exceed 40 mg.
Missed-Dose Rules	Instructions advise avoiding a double dose. If a dose is missed, it should be taken as soon as remembered unless it is near the time of the next scheduled dose.
Special Procedural Conditions	Oral administration is typically divided into two or three daily doses, with a larger portion often advised at bedtime to utilize its sedative effect. Following an IM or IV injection, the patient is required to remain recumbent (lying down) for a period.

Instruction Classifications (High-Level)

Classification	Pattern/Type
Administration Method Type	Oral, Intramuscular, Intravenous, Subcutaneous
Frequency Pattern	Divided daily use; Intermittent as-needed injection; 24-hour continuous infusion
Use-Context Constraints	Titration-Dependent: Requires gradual dose adjustment; Supervision-Dependent: Injection restricted to supervised settings for acute care.

Resulting Procedural Structure

Official Step Sequence:

The therapeutic process begins with a low, specified starting dose, which is slowly increased (titrated) until a therapeutic level is reached.
Oral intake is generally divided, leveraging the medication’s properties by shifting dosage volume to the evening.
Acute parenteral use requires strict dilution steps and may be repeated every 6 to 8 hours up to a specified maximum.

Connection to the overall use protocol (2–4 sentences): The standard instructions establish a structured protocol defining the accepted routes, precise dosage ranges, and time-dependent administration patterns for Levomepromazin. This framework mandates initial titration followed by dose reduction to a maintenance level once stability is achieved. The inclusion of dilution requirements for injection forms governs the safe and correct preparation of the medicine for supervised use.

Recent Clinical Evidence

Research evidence / Overview of studies for Levomepromazine

Evidence for Use in Acute Stabilization (Schizophrenia and Psychosis)

Research exploring Levomepromazine in the context of acute stabilization for conditions like schizophrenia has been based primarily on short-term, comparative studies. These studies, often structured as Randomized Controlled Trials (RCTs), was studied for a short duration, typically around four to eight weeks. They examined how symptoms, such as delusions, excitement, and agitation, were measured over that defined time interval. The studies measured outcomes related to overall symptom intensity using global scales.

The findings describe patterns observed in the studies that evaluated Levomepromazine. Research highlights changes measured in symptom scores during the study period. However, the available research base includes studies with sample sizes that were modest. Because of this, and the short time frame, the evidence is limited to providing insights into these immediate, acute symptomatic changes.

Evidence for Use in Supportive and Palliative Care

Levomepromazine was evaluated in settings where supportive symptomatic assistance is utilized, such as certain supportive and palliative care scenarios. Research has explored its use for outcomes related to physical discomfort and systemic or functional imbalance, specifically persistent nausea, vomiting, severe agitation, and restlessness.

Supportive Use: Evidence for Nausea, Vomiting, and Delirium

In conditions involving periods of heightened symptoms like intractable nausea and vomiting or severe delirium, research examined symptom severity and the documentation of concurrent use of other agents. Findings describe patterns observed in these open clinical settings; however, certainty remains low due to the nature of the study designs. There is a lack of high-quality comparative evidence.

Supportive Use: Evidence for Pain Management

Levomepromazine was observed in clinical studies exploring its supplementary role in studies exploring pain relief alongside primary pain relief medication. Research explored the patient-reported outcomes describing perceived discomfort and the requirements for concurrent analgesic agents. The research describes its use in specific pain contexts, such as chronic refractory pain.

Understanding Evidence Gaps and Uncertainties

The evidence base for Levomepromazine highlights several areas where certainty remains low and where more research is needed. A key limitation is the comparative evidence is lacking—specifically, the absence of controlled studies comparing Levomepromazine against a placebo for many indications. In addition, long-term effects are not fully established, and evidence quality varies across studies due to the reliance on non-randomized designs for supportive care uses.

Frequently Asked Questions (FAQ)

Common questions about Levomepromazin (FAQ)

Q: Is Levomepromazin considered a sedative?

Yes, Levomepromazin is officially classified as a potent sedative and tranquilizer. Its strong pharmacological action on the central nervous system is associated with substantial calming and hypnotic effects. This characteristic is relevant to its use for stabilizing severe mental distress.

Q: Why is Levomepromazin sometimes used for nausea and vomiting?

Official product information states that Levomepromazine’s ability to help manage nausea and vomiting is related to its activity as an antagonist, or blocker, at several receptors in the brain. This includes histamine receptors. By acting on these pathways, the medicine is described as influencing signals related to vomiting.

Q: Why might Levomepromazin be prescribed when other anti-nausea drugs haven't worked?

Official usage guidelines describe Levomepromazine as a treatment for intractable nausea and vomiting. It is often considered when other primary anti-nausea agents have not been effective. This is based on its broad receptor antagonism that provides anti-emetic action.

Q: Can Levomepromazin cause weight gain?

Regulatory documents mention weight gain as a finding observed in investigations. While it is noted in official safety information, the frequency of this effect is not commonly established across all clinical data.

Q: Can Levomepromazin affect the heart rhythm?

The medicine is associated with rare but serious cardiac risks, according to official product information. These documented effects include changes seen on an ECG, such as QT interval prolongation, which can lead to severe ventricular rhythm disorders like Torsades de pointes.

Q: Is muscle stiffness or restlessness a potential side effect?

Yes, official documents note that the medicine may cause extrapyramidal symptoms. This classification includes movement-related issues, such as Parkinsonism (which involves muscle stiffness or tremor) and motor restlessness, also known as akathisia.

Q: How long does the sedating effect of Levomepromazin typically last?

The duration of the sedating effects is related to the medicine’s biological half-life. Official pharmacological information indicates that Levomepromazine has a long half-life, meaning the effects of a single dose may last for approximately 12 to 30 hours.

Q: What common over-the-counter medicines should be avoided with Levomepromazin?

Official interaction warnings cite a risk of additive effects with other medicines. Consequently, combining Levomepromazine with any medicine—including common over-the-counter products—that cause sedation or lower blood pressure may intensify those effects.

Q: Does Levomepromazin interact with pain medicines like opioids?

Yes, the combination of Levomepromazine with opioid pain medicines carries a documented risk. Official warnings cite a risk of additive depressant effects, particularly increased sedation.

Q: Is a prior heart condition a contraindication for Levomepromazin use?

A pre-existing heart condition is generally not listed as a contraindication, which would mean it is strictly forbidden to use. However, regulatory documents indicate that the medicine requires specific caution in patients with cardiovascular disease.

Q: Is Levomepromazin suitable for use in elderly patients?

Official prescribing information indicates that a lower initial dosage is generally utilized for older adults. This is due to their increased susceptibility to effects like sedation and postural hypotension (dizziness when standing up).

Q: How does Levomepromazin affect patients who also have Parkinson's disease?

Regulatory guidance indicates that the use of Levomepromazine requires caution in patients with Parkinson's disease. This is because the medicine is associated with extrapyramidal symptoms, which are movement-related effects that can resemble or exacerbate Parkinsonism.

Q: What are the core features of Neuroleptic Malignant Syndrome (NMS)?

Neuroleptic Malignant Syndrome (NMS) is a serious, rare condition documented in official information. It is often characterized by symptoms like fever and muscle rigidity.

Q: Can Levomepromazin cause blurred vision or difficulty focusing?

Regulatory documents list blurred vision as a potential common side effect. This is related to the medicine’s anticholinergic effect on the eye’s ability to focus, known as accommodation.

Q: Can Levomepromazin affect sexual function or fertility?

Official documents describe potential effects related to hormonal changes, such as hyperprolactinaemia (a hormonal change). These changes have been noted to potentially manifest as effects such as impotence.

Q: What should be known about stopping Levomepromazin after long-term use?

Official safety warnings indicate that abrupt cessation of the drug after long-term use may carry a risk of withdrawal-related symptoms. This risk includes the rare possibility of developing Neuroleptic Malignant Syndrome (NMS).

Q: Does Levomepromazin have a risk of causing low blood pressure (hypotension)?

Yes, the medicine is known to lower blood pressure. It can cause generalized hypotension, and the effect is often more noticeable when a person stands up quickly (postural hypotension).

Q: Can Levomepromazin be used during pregnancy?

Official information states that the medicine is generally not recommended during pregnancy, particularly in the third trimester. This is due to potential risks of effects like withdrawal symptoms in the newborn.

Q: Does Levomepromazin pass into breast milk?

Official information states that while it is not definitively known if the drug is distributed into milk, the chemical properties of the medicine suggest that it may be excreted in breast milk. For this reason, use while breastfeeding is generally not recommended.

Q: Are there specific food or supplement interactions with Levomepromazin?

Yes, certain interactions related to absorption have been noted in official documents. Specifically, certain compounds, such as those found in aluminum-containing antacids, may decrease the absorption of Levomepromazine, potentially reducing its effectiveness.

Q: What should people with diabetes know about taking Levomepromazin?

Documented effects include the possibility of impaired glucose tolerance and hyperglycemia (high blood sugar). This information is relevant for people managing diabetes or those at risk for high blood sugar.

Q: Can Levomepromazin cause a change in urine color?

According to the official patient information leaflet, the presence of the medicine's metabolites may cause urine to appear darker. This is generally noted as a common effect due to the presence of metabolites.

Q: What is the general advice about driving or operating machinery while on Levomepromazin?

The medicine carries a common risk of causing drowsiness, sedation, and postural hypotension (dizziness when standing up). Due to these risks, patients are generally advised to avoid driving or operating machinery.

Q: Is the long half-life of Levomepromazin a factor in its use?

The long half-life of the medicine, reported to be approximately 15 to 30 hours, is a factor that influences the dosing schedule. This pharmacological property determines the duration of its effects in the body.

Q: What are the concerns about using Levomepromazin in patients with kidney problems?

Use in patients with kidney problems requires caution as a precaution against potential accumulation risks. Regulatory documentation indicates that dose adjustments may be utilized due to potential accumulation risks.

How should Levomepromazin be stored and disposed of?

How to Store and Dispose of Levomepromazine

This section outlines the official requirements for storing and disposing of Levomepromazine, as defined in regulatory labeling.

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Levomepromazine Injection must be stored below 25 C.
Protection	Keep the medicine in the original container to protect from light and moisture.
Child Safety	Keep out of the reach of children.
Stability	The solution for injection should be used immediately after opening, or within 24 hours in a closed system.

Disposal Instructions

To dispose of expired or unused Levomepromazine, it is required that the product be discarded in accordance with local environmental regulations. Do not dispose of the medicine in household trash or wastewater. Return unused medicine to a local pharmacy or designated collection program for proper disposal via an approved waste facility, as the active substance may require controlled waste management.

Levomepromazin